OR WAIT null SECS
June 30, 2025
Article
An audio recap of the top 5 stories in healthcare news from the week of 06/16-06/22
Stay updated with the latest healthcare breakthroughs, including new phase 2/3 clinical trial data and an FDA approval, in this week's essential news roundup.
June 27, 2025
Patients with cirrhosis receiving diuretics and SGLT-2 inhibitors experienced lower rates of serious liver events than those not taking SGLT-2 inhibitors.
June 26, 2025
Positive topline results show the trial met its primary endpoint for MASH resolution and fibrosis improvement, with significant weight loss effects without plateauing.
June 25, 2025
Topline data from the phase 1b study for the final 400 mg dose cohort demonstrate favorable safety, tolerability, and pharmacokinetics similar to the 150 mg dose cohort.
June 24, 2025
A recent cross-sectional analysis has estimated the size of the American population with both MASLD and T2DM eligible for treatment.
More frequently adding salt to food was associated with heightened risks of MASLD, cirrhosis, and hepatocellular carcinoma.
June 23, 2025
While achieving SVR was linked to improvements in fibrosis markers, hepatic steatosis prevalence increased, especially in those with metabolic dysfunctions.
Stay updated with the latest healthcare breakthroughs, including FDA approvals, clinical trial data, and novel research, in this week's essential news roundup.
June 20, 2025
Patients with alcohol-associated liver disease and MetALD had greater risks of adverse liver outcomes and all-cause mortality than those with MASLD.
